Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis"

CNS Drugs. 2019 Mar;33(3):293-295. doi: 10.1007/s40263-019-00615-5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Crotonates
  • Fingolimod Hydrochloride
  • Humans
  • Multiple Sclerosis*

Substances

  • Crotonates
  • Fingolimod Hydrochloride